MedPath

Gut Microbiome, Adiposity, and Probiotics (GMAP)

Not Applicable
Completed
Conditions
Obesity, Childhood
Interventions
Dietary Supplement: Placebo pill - soy protein powder
Dietary Supplement: Probiotic - VSL#3
Registration Number
NCT03533621
Lead Sponsor
University of California, San Diego
Brief Summary

Recent studies have shown that the bacteria in the gut (gut microbiome) can affect adiposity levels and inflammation. In animal studies, changing these bacteria has been linked with decreased fat mass and inflammation as well as improved metabolism. Probiotics can be a safe method of altering the gut microbiome in humans and have shown promising results in adults with regards to changing adiposity and inflammatory markers. However, it may also be important to provide the right dietary milieu (i.e. high fruit and vegetable/low saturated fat diet) in order to see the benefits of probiotics on these physiologic markers. At this time, no one has offered probiotics in the context of the right dietary milieu and tested it in children. This pilot proposal is innovative because it will be the first to test how well probiotics work in the context of a diet high in fruits and vegetables to change the gut microbiome, decrease fat mass, and improve inflammatory markers in overweight/obese children. This protocol will allow one to better understand the effect of probiotics on these physiologic functions and determine acceptability and feasibility of taking daily probiotics.

Detailed Description

The goal is to study the effect of probiotics on changing the gut microbiome of overweight/obese children. Since there appears to be a diet-by-microbiota interaction for optimal effects on adiposity, it will be important to administer the probiotics within the context of increased fruit/vegetable (F/V) intake and decreased fat intake. Because changes in diet alone can also induce changes in the gut microbiota, this study will use a double-blind, randomized, placebo-control design to determine whether changes in gut microbiota are greater with the addition of probiotics (High F/V diet + Probiotics) compared to diet alone (High F/V diet + Placebo). The primary aim is to test the effect of these 2 arms on changing the gut microbiota, fat mass, and inflammation in children. The study will also examine the acceptability of taking probiotics and changes in other physiologic measures.

The Specific aims of this proposal are:

1. To examine the effect of diet high in F/V +/- probiotics on change in gut microbiota, adiposity, and inflammation (measured by C-reactive protein, TNF-a, and IL-6);

2. To examine the effect of diet high in F/V +/- probiotics on physiologic measures including blood pressure, fasting insulin and glucose, and adiponectin;

3. To determine the acceptability and feasibility of taking daily probiotics over a 12 week period.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
45
Inclusion Criteria
  • BMI >= 85th percentile
  • 7-16 years old
  • parent willing to participate
Exclusion Criteria
    1. taking any oral or topical antibiotics or probiotics within the last month prior to the start of the intervention, 2) allergy to milk or milk products, 3) taking any diabetes medication, lipid-lowering drugs, or anti-inflammatory drugs, 4) be immune compromised; 5) 5% weight change or greater within the last three months, 6) psychiatric or medical illness that would hinder their ability to participate in weekly sessions, 7) receiving treatment for a major psychiatric disorder, including an eating disorder, 8) developmental delay such that the intervention materials will not be appropriate, and 9) the possibility of moving out of the area within the time frame of the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo pill - soy protein powder1 placebo pill (soy protein powder), twice a day, for 12 weeks + 20 min weekly support to increase fruit and vegetable consumption
ProbioticProbiotic - VSL#31 Probiotic pill, twice a day, for 12 weeks + 20 min weekly support to increase fruit and vegetable consumption
Primary Outcome Measures
NameTimeMethod
hsCRP12 weeks

high sensitivity C-reactive protein (mg/L) measured at baseline (week 0) and study completion (week 12)

Adiposity12 weeks

change in total % fat mass as measured by DXA scan measured at baseline (week 0) and study completion (week 12)

IL-612 weeks

Interleukin 6 (pg/ml) measured at baseline (week 0) and study completion (week 12)

Adiponectin12 weeks

adiponectin (ug/ml) measured at baseline (week 0) and study completion (week 12)

Acceptability of taking pillsweek 12

Acceptability of taking pills daily for 12 weeks assessed with 3 separate questions: Did your child take his/her pill daily (1 = not at all, 3 = sometimes, 5 = every day); Did your child have trouble remembering to take his/her pill daily (1 = not at all, easy to remember, 5 = had a lot of trouble remembering); Did your child like taking his/her pill (1 = not at all, 5 = loved it!). Parents were asked to complete these questions at study completion (week 12). The second question will be reverse-scored, and higher scores will indicate better acceptability. Each question will be viewed as separate items, and not combined to create a summary score.

Proportion of participants with side effects12 weeks

weekly assessment of any side effects reported by participants including nausea, abdominal pain, bloating, or skin reactions

TNF-alpha12 weeks

Tumor necrosis factor alpha (pg/ml) measured at baseline (week 0) and study completion (week 12)

Secondary Outcome Measures
NameTimeMethod
Bristol Stool chart12 weeks

changes in stooling pattern as assessed by the Bristol Stool Chart, measured at baseline (week 0), weekly during the study (weeks 1-11), and study completion (week 12)

gut microbiome12 weeks

Changes in the composition and alpha and beta diversity of the gut microbiome using 16SrRNA amplicon sequencing. DNA sequencing will be performed using MiSeq platforms. Samples were obtained at baseline (week 0) and study completion (week 12).

© Copyright 2025. All Rights Reserved by MedPath